Evidence map›Paper›PMID 36368709›Full record

SynthesisInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2023

Systematic mapping review of guidelines for

Brittany N Hughes, Kirsten A Jorgensen, Shelly Cummings, Damini Morah, Kate Krause, Jose Alejandro Rauh-Hain, Thomas J Herzog

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Brittany N HughesUniversity of Cincinnati Cancer Center, Cincinnati, Ohio, USA brittany.hughes04@gmail.com.ORCID 0000-0002-2111-0909
Kirsten A JorgensenGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center Division of Surgery, Houston, Texas, USA.
Shelly CummingsMyriad Genetics Inc, Salt Lake City, Utah, USA.
Damini MorahMyriad Genetics Inc, Salt Lake City, Utah, USA.
Kate KrauseThe University of Texas MD Anderson Cancer Center Research Medical Library, Houston, Texas, USA.
Jose Alejandro Rauh-HainThe University of Texas MD Anderson Cancer Center Department of Gynecologic Oncology and Reproductive Medicine, Houston, Texas, USA.
Thomas J HerzogUniversity of Cincinnati Cancer Center, Cincinnati, Ohio, USA.
The University of Texas MD Anderson Cancer Center · USMyriad Genetics · USUniversity of Cincinnati · US

Funding

Training of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2M
NCI NIH HHS T32 CA101642
6 · The paper itself

Abstract

objectiveIdentification of persons at risk for hereditary syndromes through genetic testing prior to cancer diagnosis may proactively reduce the cancer burden morbidity and mortality. Using a framework of health equity, this study characterizes the global landscape of publication and reference to

methodsThis study used a systematic literature search supplemented by an International Gynecologic Cancer Society (IGCS) informal survey and cross referenced with Myriad Genetics records, to identify published GTG, their country of origin, and countries referencing them.

resultsOf 1011 identified publications, 166 met the inclusion criteria, from which 46 unique guidelines were identified, published by 18 countries and two regions (Europe and the UK). Authorship from the USA accounted for 63% of publications on GTG. Systematic mapping reviews revealed 34 countries with published and/or referenced guidelines, the IGCS survey revealed 22 additional countries, and coordination with Myriad Genetics revealed additional information for two countries and primary information for one country. Of the 57 countries evaluated, 33% published their own guidelines and reference guidelines from another country/region, 5% published their own guidelines without referencing another country/region, and 61% only referenced a guideline from another country/region. No data were available for 138 of 195 countries, disproportionately from Africa, the Middle East, Eastern Europe, and Southeast Asia.

conclusionsGlobal geographic disparities in the publication and referencing of GTG exist, with a large emphasis on North American and European guidelines in the published literature. These disparities highlight a need for uniform

Indexed as

Genital Neoplasms, FemaleHealth EquityOvarian NeoplasmsBRCA1 ProteinCarcinoma, Ovarian EpithelialEuropeFemaleGenetic TestingHumansBRCA1 ProteinBRCA1 protein, humanBRCA1 ProteinBRCA2 ProteinGynecologyMiscellaneousOvarian Cancer

Identifiers

PMID36368709
PMCPMC12234120
OpenAlexW4308834708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.